The Case Report of Belief BioMed’s Hemophilia B Gene Therapy Drug Candidate BBM-H901 Published in The New England Journal of Medicine
Belief BioMed’s AAV-based Gene Therapy Drug Candidate Receives China CDE’s Breakthrough Therapy Designation
Belief BioMed’s AAV-based Gene Therapy Drug Candidate was Granted Orphan Drug Designation by the FDA
Belief BioMed Co-Founder and CEO Dr. Jane Zheng was Selected by Forbes as One of the "50 Chinese Women in Science and Technology"!
Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B
Remarkable success once more! Belief BioMed won the award of "the 10th China Innovation and Entrepreneurship Competition Excellent Enterprise"
2021 Future Medical Industry Summit, Dr. Xiao Xiao【Gene Therapy: Expansion from Rare Disease to Common Medicine】
Belief Biomed’s Gene Therapy for Hemophilia B Receives NMPA IND Approval: First Intravenous Infusion Gene Therapy for Rare Disease in China
Belief BioMed seized the new developing opportunity of Lin-gang and signed a contract to construct the key project in Lin-gang Biotechnology Industrial Park